Description

Venofer 20mg/ml 5 ampoules

Ingredients:

Each ampoule contains 100 mg of iron sucrose in 5 ml solution.

Dosage:

The recommended dose is determined by the healthcare provider based on the patient’s iron deficiency anemia condition. It is usually administered as an intravenous infusion over a period of time.

Indications:

Venofer is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease receiving hemodialysis. It is also used in non-dialysis dependent chronic kidney disease patients with iron deficiency anemia.

Contraindications:

Do not use Venofer in patients with known hypersensitivity to iron products or in patients with anemia not caused by iron deficiency. It should not be used in patients with evidence of iron overload.

Directions:

Venofer should be administered under the supervision of a healthcare provider experienced in the management of patients with anemia. The dosage and infusion rate should be carefully monitored.

Scientific Evidence:

Venofer, with its iron sucrose formulation, has shown significant efficacy in treating iron deficiency anemia in various patient populations. Studies have demonstrated its ability to rapidly increase hemoglobin levels and replenish iron stores effectively. Research by Macdougall et al. (2006) highlighted the favorable safety profile and efficacy of Venofer in hemodialysis patients.

Additional Information:

In clinical trials, Venofer has been well-tolerated with minimal adverse effects. Its convenient dosing regimen and lower risk of anaphylaxis compared to other iron preparations make it a preferred choice in the management of iron deficiency anemia. Patients receiving Venofer have reported improved quality of life and reduced transfusion requirements, further supporting its clinical benefits.

Pharmacological Effects: Venofer works by providing a controlled release of iron, which is essential for the production of hemoglobin and red blood cells. The iron sucrose complex allows for a gradual release of iron, reducing the risk of oxidative stress and adverse reactions associated with rapid iron infusion.

Clinical Trials: Comparative studies have shown Venofer to be as effective as other intravenous iron formulations but with a lower incidence of side effects. A study by Charytan et al. (2015) demonstrated the non-inferiority of Venofer compared to iron dextran in hemodialysis patients, emphasizing its role as a safe and efficacious treatment option.